相关实验视频

Updated: Sep 13, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

宝河平安威功率加新辅助化疗治疗胃癌

Hong-Yu Ma^1,2, Xin Liu^3,4,5, Yuan-Wu Chen⁶

¹Department of Spleen and Stomach Diseases, First Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang 050011, Hebei Province, China.

World journal of gastrointestinal surgery

|July 31, 2025

概括

与化疗相结合的Baohe Pingwei粉末显著改善了胃癌 (GC) 患者的治疗结果,提高了反应率和生存率. 这种传统中医药可以减少不良事件,并为GC管理提供一个有前途的综合方法.

科学领域:

综合性瘤学是一种综合性瘤学.
胃肠道瘤学胃肠道瘤学
传统中医 (TCM) 在癌症护理中的作用

背景情况:

新辅助化疗增强胃癌 (GC) 切除率,但导致毒性.
作为TCM的一种Baohe Pingwei粉末可以减轻化疗副作用并提高疗效.
在术后的GC患者中缺乏Baohe Pingwei粉末的临床证据.

研究的目的:

评估Baohe Pingwei粉末加上新辅助化疗在术后GC患者的安全性和有效性.
在GC治疗中提供综合传统中国和西方医学的证据.

主要方法:

80名术后GC患者的回顾性分析 (2024年5月至11月).
对照组 (n=54):S-1 + 氧化化疗.
研究组 (n=26):宝河平伟粉末 + S-1 + 氧化.
客观反应率 (ORR),疾病控制率 (DCR),生存率和不良事件的比较.
后勤回归和Cox风险模型分析了疗效预测因素.

主要成果:

与对照组 (ORR 46.30%, DCR 70.37%) 相比,研究组的ORR (84.62%) 和DCR (92.31%) 显著更高.
宝河平粉的使用与复发和死亡风险降低有关 (日志等级P<0.05).
较高的CD3 +,CD4 + T细胞水平和Baohe Pingwei粉末的使用预测了有效的治疗.
较高的CA19-9和IL-6水平是治疗无效的独立风险因素.

结论:

与Baohe Pingwei粉末的联合治疗改善了手术后GC患者的ORR,DCR和存活率.
这种综合方法减少了与治疗相关的不良事件.
减少CD3+/CD4+T细胞和CA19-9/IL-6升高是治疗失败风险的生物标志物.

关键词:

宝河平伟粉末是什么意思有效性有效性.胃癌胃癌是指胃癌.新辅助化学疗法新辅助化学疗法安全的安全的安全的安全的安全.

更多相关视频

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment

Published on: December 27, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...